Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–36 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Ulcerative Colitis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Chula Vista, California • La Jolla, California • Rialto, California + 8 more
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

NCT07446101
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
5
States / cities
Daytona Beach, Florida • Dilworth, Minnesota • Dallas, Texas + 2 more
Conditions
Ulcerative Colitis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Orange, California • San Francisco, California • Denver, Colorado + 18 more
Conditions
Lactation, Inflammatory Bowel Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
3 Weeks and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Glenview, Illinois • Iowa City, Iowa • Baltimore, Maryland + 2 more
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more
Conditions
Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
54
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
Conditions
Ulcerative Colitis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
98
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 83 more
Conditions
Crohn's Disease, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
49
States / cities
Litchfield Park, Arizona • Sun City, Arizona • Lancaster, California + 41 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

NCT05644353
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Cypress, California • Daytona Beach, Florida • Miami, Florida + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

NCT05069896
Conditions
Healthy
Interventions
Mirikizumab Prefilled Syringe, Mirikizumab Autoinjector
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas
Conditions
Psoriasis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Farmington, Connecticut • Coral Gables, Florida • Ocala, Florida + 7 more